Affordable Access

deepdyve-link
Publisher Website

Chinese herbal medicine (Rupi Sanjie capsule) for the treatment of breast pain: A systematic review and meta-analysis of randomized clinical trials.

Authors
  • Lai, Bao-Yong1
  • Jia, Li-Yan2
  • Yu, Bo-Wen1
  • Liang, Shi-Bing3
  • Chu, Ai-Jing1
  • Cao, Hui-Juan3
  • Liu, Jian-Ping3
  • Pei, Xiao-Hua1, 4
  • 1 Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China. , (China)
  • 2 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. , (China)
  • 3 Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. , (China)
  • 4 The Fangshan Hospital of Beijing Universality of Chinese Medicine, Beijing, China. , (China)
Type
Published Article
Journal
Integrative medicine research
Publication Date
Jun 01, 2021
Volume
10
Issue
2
Pages
100491–100491
Identifiers
DOI: 10.1016/j.imr.2020.100491
PMID: 33134080
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Breast pain is one of the most common breast disorders, affecting 41%-69% women in the clinical populations. Chinese herbal medicine (Rupi Sanjie, RPSJ) capsule has been recommended to be commonly used for breast pain in China. This review aimed to systematically collect latest evidence and critically evaluate the eff ;ectiveness and safety of RPSJ capsule for breast pain. We searched 6 databases from their inception to June 1, 2020 for randomized clinical trials (RCTs) comparing RPSJ capsule with conventional drug therapies, placebo or no treatment. Primary outcomes were breast pain relief, reduction of breast mass and clinical cure rate. Seventeen RCTs were included in total, involving 2899 participants with breast pain. RPSJ capsule showed a significant effects in shortening duration of the breast pain (MD-6.51 days, 95%CI [-8.57, -4.45], n = 82, 1 trial), shortening the duration of breast mass (MD-5.17 days, 95%CI [-7.56, -2.78], n = 82, 1 trial), improving clinical cure rate (RR 1.55, 95% CI [1.21, 2.00], I² = 64%, n = 1398, 10 trials) and total effective rate (RR 1.08, 95% CI [1.03, 1.14], I² = 71%, n = 2170, 14 trials) compared to Tamoxifen (TAM). The meta-analysis showed that the incidence of total adverse events was higher in TAM group than the RPSJ capsule group (RR 0.30, 95%CI [0.21, 0.42], I² = 49%, n = 2122, 13 trials). RPSJ capsule appears to be a potentially effective in treating breast pain and seems generally safe for clinical application. However, this potential benefit is inconclusive due to generally weak evidence, and the findings should be further confirmed in large and rigorous trials. © 2020 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V.

Report this publication

Statistics

Seen <100 times